巨噬细胞移动抑制因子在肌萎缩侧索硬化症治疗中的转化挑战 - Suppr

Translational challenges in amyotrophic lateral sclerosis therapy with macrophage migration inhibitory factor.

作者信息

Alfahel Leenor, Rajkovic Aleksandar, Israelson Adrian

机构信息

Department of Physiology and Cell Biology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; The School of Brain Sciences and Cognition, Ben-Gurion University of the Negev, Beer Sheva, Israel.

出版信息

Neural Regen Res. 2025 Sep 1;20(9):2583-2584. doi: 10.4103/NRR.NRR-D-24-00616. Epub 2024 Sep 24.

DOI:10.4103/NRR.NRR-D-24-00616

PMID:39503423

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11801292/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4078/11801292/2c6d8d0b5c31/NRR-20-2583-g001.jpg

相似文献

Translational challenges in amyotrophic lateral sclerosis therapy with macrophage migration inhibitory factor.

Neural Regen Res. 2025 Sep 1;20(9):2583-2584. doi: 10.4103/NRR.NRR-D-24-00616. Epub 2024 Sep 24.

Targeting Macrophage for the Treatment of Amyotrophic Lateral Sclerosis.

CNS Neurol Disord Drug Targets. 2019;18(5):366-371. doi: 10.2174/1871527318666190409103831.

Leukemia inhibitory factor induces epidermal hyperplasia in patients with amyotrophic lateral sclerosis.

J Invest Dermatol. 2000 Sep;115(3):486-92. doi: 10.1046/j.1523-1747.2000.00047.x.

Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord.

Brain. 2022 Sep 14;145(9):3108-3130. doi: 10.1093/brain/awac165.

Cell-mediated immunity to polio and HLA antigens in amyotrophic lateral sclerosis.

Neurology. 1979 Jul;29(7):1040-4. doi: 10.1212/wnl.29.7.1040.

MTHFSD and DDX58 are novel RNA-binding proteins abnormally regulated in amyotrophic lateral sclerosis.

Brain. 2016 Jan;139(Pt 1):86-100. doi: 10.1093/brain/awv308. Epub 2015 Nov 2.

Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.

Drug Saf. 2022 Jun;45(6):663-673. doi: 10.1007/s40264-022-01184-1. Epub 2022 May 24.

Intervirology. 1989;30(4):202-12. doi: 10.1159/000150094.

MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design.

Neurodegener Dis Manag. 2021 Dec;11(6):431-443. doi: 10.2217/nmt-2021-0042. Epub 2021 Nov 24.

MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia.

Brain Commun. 2021 May 27;3(2):fcab114. doi: 10.1093/braincomms/fcab114. eCollection 2021.

本文引用的文献

Targeting low levels of MIF expression as a potential therapeutic strategy for ALS.

Cell Rep Med. 2024 May 21;5(5):101546. doi: 10.1016/j.xcrm.2024.101546. Epub 2024 May 3.

Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor.

EMBO Mol Med. 2024 Apr;16(4):945-965. doi: 10.1038/s44321-024-00037-x. Epub 2024 Feb 27.

MIF contribution to progressive brain diseases.

J Neuroinflammation. 2024 Jan 4;21(1):8. doi: 10.1186/s12974-023-02993-6.

Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.

Nat Nanotechnol. 2023 Oct;18(10):1241-1251. doi: 10.1038/s41565-023-01419-x. Epub 2023 Jul 10.

Trial of Antisense Oligonucleotide Tofersen for ALS.

N Engl J Med. 2022 Sep 22;387(12):1099-1110. doi: 10.1056/NEJMoa2204705.

AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset.

Nat Neurosci. 2022 Jan;25(1):106-115. doi: 10.1038/s41593-021-00969-4. Epub 2021 Dec 9.

Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for ALS.

N Engl J Med. 2020 Jul 9;383(2):109-119. doi: 10.1056/NEJMoa2003715.

The Dichotomic Role of Macrophage Migration Inhibitory Factor in Neurodegeneration.

Int J Mol Sci. 2020 Apr 24;21(8):3023. doi: 10.3390/ijms21083023.

Brain-derived neurotrophic factor mediates macrophage migration inhibitory factor to protect neurons against oxygen-glucose deprivation.

Neural Regen Res. 2020 Aug;15(8):1483-1489. doi: 10.4103/1673-5374.274340.

AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS.

Proc Natl Acad Sci U S A. 2019 Jul 16;116(29):14755-14760. doi: 10.1073/pnas.1904665116. Epub 2019 Jul 1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Translational challenges in amyotrophic lateral sclerosis therapy with macrophage migration inhibitory factor.

作者信息

Alfahel Leenor, Rajkovic Aleksandar, Israelson Adrian

机构信息

出版信息

Neural Regen Res. 2025 Sep 1;20(9):2583-2584. doi: 10.4103/NRR.NRR-D-24-00616. Epub 2024 Sep 24.

DOI:10.4103/NRR.NRR-D-24-00616

PMID:39503423

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11801292/

Abstract

摘要

相似文献

Translational challenges in amyotrophic lateral sclerosis therapy with macrophage migration inhibitory factor.

Neural Regen Res. 2025 Sep 1;20(9):2583-2584. doi: 10.4103/NRR.NRR-D-24-00616. Epub 2024 Sep 24.

Targeting Macrophage for the Treatment of Amyotrophic Lateral Sclerosis.

CNS Neurol Disord Drug Targets. 2019;18(5):366-371. doi: 10.2174/1871527318666190409103831.

Leukemia inhibitory factor induces epidermal hyperplasia in patients with amyotrophic lateral sclerosis.

J Invest Dermatol. 2000 Sep;115(3):486-92. doi: 10.1046/j.1523-1747.2000.00047.x.

Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord.

Brain. 2022 Sep 14;145(9):3108-3130. doi: 10.1093/brain/awac165.

Cell-mediated immunity to polio and HLA antigens in amyotrophic lateral sclerosis.

Neurology. 1979 Jul;29(7):1040-4. doi: 10.1212/wnl.29.7.1040.

MTHFSD and DDX58 are novel RNA-binding proteins abnormally regulated in amyotrophic lateral sclerosis.

Brain. 2016 Jan;139(Pt 1):86-100. doi: 10.1093/brain/awv308. Epub 2015 Nov 2.

Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.

Drug Saf. 2022 Jun;45(6):663-673. doi: 10.1007/s40264-022-01184-1. Epub 2022 May 24.

Intervirology. 1989;30(4):202-12. doi: 10.1159/000150094.

MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design.

Neurodegener Dis Manag. 2021 Dec;11(6):431-443. doi: 10.2217/nmt-2021-0042. Epub 2021 Nov 24.

MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia.

Brain Commun. 2021 May 27;3(2):fcab114. doi: 10.1093/braincomms/fcab114. eCollection 2021.

本文引用的文献

Targeting low levels of MIF expression as a potential therapeutic strategy for ALS.

Cell Rep Med. 2024 May 21;5(5):101546. doi: 10.1016/j.xcrm.2024.101546. Epub 2024 May 3.

Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor.

EMBO Mol Med. 2024 Apr;16(4):945-965. doi: 10.1038/s44321-024-00037-x. Epub 2024 Feb 27.

MIF contribution to progressive brain diseases.

J Neuroinflammation. 2024 Jan 4;21(1):8. doi: 10.1186/s12974-023-02993-6.

Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.

Nat Nanotechnol. 2023 Oct;18(10):1241-1251. doi: 10.1038/s41565-023-01419-x. Epub 2023 Jul 10.

Trial of Antisense Oligonucleotide Tofersen for ALS.

N Engl J Med. 2022 Sep 22;387(12):1099-1110. doi: 10.1056/NEJMoa2204705.

AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset.

Nat Neurosci. 2022 Jan;25(1):106-115. doi: 10.1038/s41593-021-00969-4. Epub 2021 Dec 9.

Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for ALS.

N Engl J Med. 2020 Jul 9;383(2):109-119. doi: 10.1056/NEJMoa2003715.

The Dichotomic Role of Macrophage Migration Inhibitory Factor in Neurodegeneration.

Int J Mol Sci. 2020 Apr 24;21(8):3023. doi: 10.3390/ijms21083023.

Brain-derived neurotrophic factor mediates macrophage migration inhibitory factor to protect neurons against oxygen-glucose deprivation.

Neural Regen Res. 2020 Aug;15(8):1483-1489. doi: 10.4103/1673-5374.274340.

AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS.

Proc Natl Acad Sci U S A. 2019 Jul 16;116(29):14755-14760. doi: 10.1073/pnas.1904665116. Epub 2019 Jul 1.

Translational challenges in amyotrophic lateral sclerosis therapy with macrophage migration inhibitory factor.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Translational challenges in amyotrophic lateral sclerosis therapy with macrophage migration inhibitory factor.

作者信息

机构信息

出版信息

相似文献

本文引用的文献